Evicenter
MarkdownMedical informationP&T meetings
Rinzimetostat (ORIC-944)

Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide

Regulatory status
Not announced
Launch
Not announced
Last updated
165 sources

Economic information and modeling reportBudget impact model

Budget impact model discussion

1 evidence topic · 10 sources

Summary: inputs available and absence of a rinzimetostat price or model

No budget impact model of rinzimetostat was identified, and no rinzimetostat price has been published: ORIC has “no products approved for commercial sale”, and its $3.5 billion U.S. addressable market figure “assumes current price of ARPIs for illustrative purposes”. A plan building its own model would need the rinzimetostat price and the regimen studied in Himalayas-1, rinzimetostat 400 mg once daily with darolutamide 600 mg twice daily. Published population inputs are ORIC's estimate of approximately 17,000 U.S. patients annually with mCRPC previously treated with abiraterone (company-reported), a modeled U.S. mCRPC incidence of 42,970 in 2020, and Medicare fee-for-service data in which abiraterone accounted for 36% of first-line mCRPC therapy and 42% of men received at least two lines. Published cost inputs are the darolutamide wholesale acquisition cost of $15,100.80 per bottle of 120 tablets of 300 mg (effective 1 January 2026), the 2027 Medicare negotiated price for enzalutamide of $7,004 per 30-day supply, and Medicare Part B payment limits for October to December 2026 for docetaxel ($0.471 per mg) and cabazitaxel ($231.688 per mg).